230 related articles for article (PubMed ID: 24737786)
1. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
[TBL] [Abstract][Full Text] [Related]
2. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
3. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
JAMA Intern Med; 2013 Aug; 173(15):1407-14. PubMed ID: 23817631
[TBL] [Abstract][Full Text] [Related]
4. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
[TBL] [Abstract][Full Text] [Related]
5. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
Lyseng-Williamson KA; Foster RH
Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
[TBL] [Abstract][Full Text] [Related]
6. Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
Miller H; Wallman JK; Petersson IF; Saevarsdottir S; Söderling J; Ernestam S; Askling J; van Vollenhoven R; Neovius M
Rheumatology (Oxford); 2021 May; 60(5):2217-2222. PubMed ID: 33179071
[TBL] [Abstract][Full Text] [Related]
7. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
9. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
Wong JB; Singh G; Kavanaugh A
Am J Med; 2002 Oct; 113(5):400-8. PubMed ID: 12401535
[TBL] [Abstract][Full Text] [Related]
10. Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.
Eriksson JK; Wallman JK; Miller H; Petersson IF; Ernestam S; Vivar N; van Vollenhoven RF; Neovius M
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1758-1766. PubMed ID: 27015295
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
Kobelt G; Jönsson L; Young A; Eberhardt K
Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
[TBL] [Abstract][Full Text] [Related]
12. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Mora C; González A; Díaz J; Quintana G
Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
Jalal H; O'Dell JR; Bridges SL; Cofield S; Curtis JR; Mikuls TR; Moreland LW; Michaud K
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1751-1757. PubMed ID: 27015606
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
16. Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.
Olofsson T; Wallman JK; Jöud A; Schelin MEC; Ernestam S; van Vollenhoven R; Saevarsdottir S; Lampa J
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1312-1321. PubMed ID: 32433827
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
[TBL] [Abstract][Full Text] [Related]
18. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
[TBL] [Abstract][Full Text] [Related]
19. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]